Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904. In addition, Merck has the option to co-promote both assets in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231027000141/en/
Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business of Merck (Photo: Business Wire)
“This partnership with Hengrui fully aligns with both our external innovation ambition and our oncology research and development strategy by diversifying our robust internal pipeline in our focus areas of DNA damage response inhibition and antibody-drug conjugates,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business of Merck. “The synergies of these assets with our portfolio offer broad potential for development and the opportunity to advance more therapeutic options for patients with difficult-to-treat cancers. We look forward to leveraging the significant expertise of Hengrui and our strong collaboration ahead.”
Compared with first-generation PARP inhibitors, the selectivity and differentiated safety profile of PARP1-specific inhibitors could offer the opportunity to expand their therapeutic impact in established and new indications. HRS-1167 has shown encouraging signs of clinical activity and patient benefit in Phase I trials as a monotherapy and has higher potential to combine with chemotherapy as well as novel agents, compared with previous attempts with first-generation PARP inhibitors. This aligns with the company’s overarching development approach of DNA damage response (DDR) inhibitors, exploring their synergistic activity and maximizing their potential impact in combination with other anticancer therapies and approaches. Merck is researching the potential to treat cancer through inhibition of multiple targets in the DDR cascade, including ATR, ATM, DNA-PK, and PARP.
Additionally, should the company exercise its option, SHR-A1904 would complement Merck’s internal preclinical and clinical ADC portfolio applying different linker payload technologies. The first ADC developed using Merck’s own technology, M9140, a CEACAM5-targeting ADC, is being evaluated in an ongoing Phase Ia/b study in patients with metastatic colorectal cancer.
"Given the high unmet need in oncology, we are excited to work closely with Merck to bring Hengrui's innovations to cancer patients worldwide,” said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma. “Partnering with Merck on our PARP franchise is an important milestone on Hengrui's globalization journey. We look forward to advancing our molecules rapidly through development and reaching patients in need.”
Under the terms of the agreement, Merck will provide Hengrui with an upfront payment of €160 million. Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Potential payments may total up to €1.4 billion.
Advancing the Future of Cancer Care
At Merck, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Phone: +49 151 1454 7809
Phone: +49 6151 72-3321
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Obsidian Security Recognized as Strong Performer by Independent Research Firm11.12.2023 17:18:00 CET | Press release
We’re thrilled to share that Obsidian Security has been named a Strong Performer while receiving the highest scores possible across five criteria in The Forrester Wave™: SaaS Security Posture Management, Q4 2023 – the first Forrester Wave(™) report to be released in the SaaS Security and Posture Management (SSPM) category. Forrestergave the Obsidian Posture Management module the highest scores possible in the configuration drift detection and SaaS app configuration templates criteria. Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion. Forrester also gave Obsidian the highest score possible in the IAM administration criterion supported by Obsidian Advanced Threat Mitigation module. The Forrester report recognized Obsidian as a vendor providing “a single, modular platform” for SaaS Security and Posture Management. The Obsidian Advanced Threat Mitigation module covers authentication monitoring and remediation,
Transition Industries LLC and Macquarie Group Announce Marketing Agreement for Low Carbon Methanol Project in Sinaloa, Mexico11.12.2023 15:13:00 CET | Press release
Transition Industries LLC announced at COP 28 that it has entered into a Master Services and Marketing Agreement (MSMA) with Macquarie Commodities Trading, an affiliate of Macquarie Group’s Commodities and Global Markets business (“Macquarie” / “CGM”), for its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico (“Pacifico Mexinol” or the “Project”). When it commences operations, Pacifico Mexinol is expected to be one of the largest single low carbon chemicals facilities in the world - producing approximately 300,000 MT of green methanol from captured carbon and green hydrogen and 1.8 million MT of blue methanol per year from natural gas with carbon capture. Under the terms of the MSMA, Macquarie is responsible for marketing all the production from Pacifico Mexinol to customers on a global basis in accordance with methanol offtake agreements, the provisioning of financial hedging services as required by the Project, and supporting
SLB Collaborates with Northern Lights JV and Microsoft to Digitalize Carbon Capture and Storage Value Chain11.12.2023 15:00:00 CET | Press release
SLB (NYSE: SLB) and Northern Lights Joint Venture (NL) announced today they have signed a memorandum of understanding (MoU) with Microsoft to optimize integrated cloud-based workflows for the operation of Northern Lights, one of the first CO2 transport and storage providers for cross-border carbon capture and storage (CCS). The collaboration will contribute to the development of scalable and cost-efficient digital solutions for the emerging CCS industry. “Digital workflows are a key component to successfully managing CO2 through the end-to-end value chain, from capture point to permanent storage. Northern Lights is very pleased to partner with industry leading tech companies, SLB and Microsoft, on the development of digital CCS solutions”, said Børre Jacobsen, Managing Director of Northern Lights. In the initial phases of the collaboration, SLB will extend its digital CCS workflows and numerical simulation systems on its Delfi™ digital platform, which was deployed to streamline the sub
New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life11.12.2023 15:00:00 CET | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analysed baseline data collected prior to initiation of study treatment and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS). “CTCL is a chronic, life-long condition. Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors. “The data provide new insights into the burdens of living with CTC
Battery Manufacturer Hithium Opens New 28 GWh Intelligent Production Plant11.12.2023 15:00:00 CET | Press release
Stationary energy storage expert Hithium will release 28 GWh planned production capacity successively at first stage of Phase 1 of its new base in Chongqing, China. The new plant is designed in line with "Intelligent Manufacturing 4.0" standards, including a 26% increase in automation over the typical "Intelligent Manufacturing 3.0" production system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211098435/en/ Hithium Chongqing production plant (Photo: Business Wire) Hithium’s automation gains at Chongqing have resulted in an overall efficiency jump of 30%, as well as cost reductions amounting to a quarter of production overhead, delivering a significant lead in manufacturing competitiveness. Built with an investment of RMB13 billion ($1.8 billion), the site covers 800,000 m2 and is located in the Tongliang high-tech zone. The new capacity aims at helping to meet global demand for what is expected to be 720GW of energy s